Your browser is no longer supported. Please, upgrade your browser.
CLDX Celldex Therapeutics, Inc. daily Stock Chart
Celldex Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.44 Insider Own0.20% Shs Outstand143.57M Perf Week0.70%
Market Cap74.48M Forward P/E- EPS next Y-0.58 Insider Trans6.10% Shs Float142.74M Perf Month-11.07%
Income-196.00M PEG- EPS next Q-0.14 Inst Own48.80% Short Float3.75% Perf Quarter-34.34%
Sales15.30M P/S4.87 EPS this Y31.10% Inst Trans-8.37% Short Ratio1.49 Perf Half Y-80.71%
Book/sh0.95 P/B0.55 EPS next Y-6.50% ROA-60.40% Target Price4.13 Perf Year-78.38%
Cash/sh0.86 P/C0.60 EPS next 5Y- ROE-86.20% 52W Range0.48 - 3.26 Perf YTD-81.73%
Dividend- P/FCF- EPS past 5Y3.20% ROI-49.20% 52W High-84.09% Beta2.40
Dividend %- Quick Ratio5.50 Sales past 5Y2.60% Gross Margin- 52W Low8.08% ATR0.03
Employees192 Current Ratio5.50 Sales Q/Q173.30% Oper. Margin- RSI (14)36.45 Volatility4.19% 5.71%
OptionableYes Debt/Eq0.00 EPS Q/Q-200.90% Profit Margin- Rel Volume0.68 Prev Close0.51
ShortableYes LT Debt/Eq0.00 EarningsAug 09 AMC Payout- Avg Volume3.59M Price0.52
Recom2.50 SMA20-1.36% SMA50-15.03% SMA200-74.40% Volume2,452,467 Change1.73%
Aug-01-17Resumed H.C. Wainwright Buy $10
Nov-07-16Initiated Aegis Capital Buy
Mar-08-16Downgrade Jefferies Buy → Hold
Mar-07-16Downgrade Wedbush Outperform → Neutral $4
Mar-07-16Downgrade Leerink Partners Outperform → Mkt Perform
Mar-07-16Downgrade Guggenheim Buy → Neutral
Mar-01-16Initiated H.C. Wainwright Buy $25
Aug-11-15Reiterated ROTH Capital Buy $43 → $39
Aug-11-15Reiterated Oppenheimer Outperform $45 → $42
Aug-11-15Reiterated Brean Capital Buy $35 → $31
Jun-02-15Reiterated WBB Securities Strong Buy $30 → $40
Nov-17-14Reiterated ROTH Capital Buy $40 → $43
Mar-04-14Reiterated Oppenheimer Outperform $40 → $36
Jul-08-13Reiterated Cantor Fitzgerald Buy $16 → $24
Mar-08-13Reiterated Cantor Fitzgerald Buy $13 → $16
Feb-26-13Reiterated Oppenheimer Outperform $10 → $13
Jan-10-13Reiterated Cantor Fitzgerald Buy $9 → $13
Oct-02-12Reiterated Oppenheimer Outperform $6 → $8
Sep-14-12Reiterated Cantor Fitzgerald Buy $7 → $9
Apr-04-12Initiated Cantor Fitzgerald Buy $7
Jul-02-18 02:18PM  How David Gardner's Biggest Losers Demonstrate Why Long-Term Investing Wins Motley Fool
Jun-29-18 08:17AM  Better Buy: Ziopharm Oncology, Inc. vs. Celldex Therapeutics Motley Fool
Jun-21-18 08:00AM  Complimentary Technical Snapshots on Celgene and Three More Biotech Stocks ACCESSWIRE
Jun-11-18 06:32AM  Celldex Therapeutics (CLDX) Down 9.2% Since Earnings Report: Can It Rebound? Zacks
Jun-02-18 04:12PM  Celldex Presents Promising Data from Phase 1/2 Study of Varlilumab and Opdivo® at 2018 ASCO Annual Meeting GlobeNewswire
Jun-01-18 11:30AM  Celldex Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference GlobeNewswire
May-18-18 07:05AM  Audentes Therapeutics and Three More Stocks Under Scanner in the Biotech Space ACCESSWIRE
May-16-18 05:01PM  Celldex Announces Presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
May-15-18 02:43PM  May Insights Into Healthcare Stocks: Celldex Therapeutics Inc (NASDAQ:CLDX) Simply Wall St.
May-11-18 09:59AM  Celldex (CLDX) Q1 Loss Wider Than Expected, Shares Down Zacks
May-10-18 03:16PM  Celldex Therapeutics Moves Forward After Glemba Clinical Failure Motley Fool -6.48%
09:00AM  Celldex (CLDX) Q1 Loss Narrower, Revenues Beat, Shares Down Zacks
08:41AM  Celldex: 1Q Earnings Snapshot Associated Press
08:00AM  Celldex Provides Corporate Update and Reports First Quarter 2018 Results GlobeNewswire
May-03-18 10:24AM  What's in Store for Celldex (CLDX) This Earnings Season? Zacks
Apr-25-18 10:33AM  Lessons to Learn From April's Biotech Blowups Motley Fool
Apr-23-18 11:20AM  Is It Game Over for Celldex? Motley Fool
Apr-22-18 10:50AM  Johnson & Johnson's First-Quarter 2018 Earnings Review Motley Fool
Apr-20-18 08:01AM  Data from Multiple Celldex Programs Presented at American Association for Cancer Research (AACR) Annual Meeting 2018 GlobeNewswire
07:55AM  Analysis: Positioning to Benefit within Celldex Therapeutics, McDermott International, Briggs & Stratton, Tile Shop Hldgs, Essendant, and Anworth Mortgage Asset Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Apr-18-18 10:07AM  Biotech Stock Roundup: ALKS Up, CLDX Down, ALXN to Acquire Wilson Therapeutics Zacks -8.10%
Apr-17-18 09:55AM  Celldex's Phase II Breast Cancer Study Fails, Shares Plunge Zacks
08:10AM  Todays Research Reports on Stocks to Watch: Celldex Therapeutics and Cancer Genetics ACCESSWIRE
Apr-16-18 08:50AM  Why Celldex Therapeutics Stock Is Cratering Today Motley Fool -64.60%
07:45AM  Celldex's stock plummets toward record low after failed drug study MarketWatch
07:00AM  Celldexs METRIC Study in Metastatic Triple-negative Breast Cancer Does Not Meet Primary Endpoint GlobeNewswire
Apr-10-18 08:46AM  Implied Volatility Surging for Celldex Therapeutics (CLDX) Stock Options Zacks
Apr-03-18 04:15PM  Celldex Therapeutics Inc (NASDAQ:CLDX): Has Recent Earnings Growth Beaten Long-Term Trend? Simply Wall St.
06:33AM  3 Top Small-Cap Biotech Stocks for Aggressive Investors Motley Fool
Mar-26-18 05:58PM  Celldex Therapeutics Inc (NASDAQ:CLDX): Are Analysts Optimistic? Simply Wall St.
Mar-16-18 04:14PM  What Do Analysts Think About Celldex Therapeutics Incs (NASDAQ:CLDX) Future? Simply Wall St.
Mar-13-18 06:33AM  Why Celldex Therapeutics Stock Crashed in February Motley Fool -8.51%
06:32AM  Is Celldex Therapeutics Stock About to Skyrocket? Motley Fool
Mar-12-18 04:17PM  3 Top Healthcare Stocks to Buy in March Motley Fool
Mar-09-18 04:21PM  Edited Transcript of CLDX earnings conference call or presentation 7-Mar-18 9:30pm GMT Thomson Reuters StreetEvents
07:31AM  Celldex Therapeutics: Make-or-Break-It Data Expected Soon Motley Fool
Mar-08-18 04:40PM  Why Celldex Therapeutics Shot Up Today Motley Fool +11.34%
10:51AM  Celldex (CLDX) Q4 Loss Narrows, Revenues Beat, Shares Up Zacks
10:33AM  Celldex Therapeutics Finishes 2017 With Plenty of Cash and High Hopes Motley Fool
08:20AM  Todays Research Reports on Trending Tickers: Celldex Therapeutics, Inc. and Geron Corporation ACCESSWIRE
Mar-07-18 04:47PM  Celldex reports 4Q loss Associated Press
04:01PM  Celldex Provides Corporate Update and Reports Full Year 2017 Results GlobeNewswire
12:30PM  Celldex Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Mar-05-18 11:11AM  What's in the Cards for Merck KGaA (MKGAF) in Q4 Earnings? Zacks
09:35AM  What's in Store for Catalyst (CPRX) This Earnings Season? Zacks
Mar-02-18 03:15PM  Celldex to Report Fourth Quarter and Year-End 2017 Business/Financial Results and Present at Upcoming Investor Conference GlobeNewswire
Mar-01-18 04:30PM  Is a Beat in the Cards for Celldex (CLDX) in Q4 Earnings? Zacks
Feb-16-18 07:17AM  3 Stocks That Could Put Tesla's Returns to Shame Motley Fool
Feb-15-18 08:25AM  Investor Expectations to Drive Momentum within Workday, The Medicines, Celldex Therapeutics, Lannett, Oclaro, and Antares Pharma Discovering Underlying Factors of Influence GlobeNewswire
Jan-31-18 07:31AM  Is Celldex Therapeutics, Inc. (CLDX) a Buy? Motley Fool
Jan-27-18 09:31AM  What to Expect From Celldex Therapeutics, Inc. in 2018 Motley Fool
Jan-21-18 11:00AM  3 Growth Stocks That Could Put Shopify's Returns to Shame Motley Fool
Jan-16-18 08:30AM  Will 2018 Be Celldex Therapeutics, Inc.'s Best Year Yet? Motley Fool
Jan-09-18 04:37PM  AbbVie's Upadacitinib Gains Breakthrough Therapy Designation Zacks
10:42AM  Amgen Announces Acceptance of MAA for Evenity in Europe Zacks
Jan-08-18 05:54PM  Ultragenyx Announces Interim Data from Early Stage Study Zacks
Jan-03-18 07:29AM  3 Biotech Stocks to Buy in January Motley Fool
Jan-02-18 08:57AM  4 Reasons to Include Celldex (CLDX) Stock in Your Portfolio Zacks
Dec-29-17 09:55AM  TherapeuticsMD Submits NDA for VMS Candidate, Shares Rise Zacks
Dec-21-17 09:53AM  AbbVie's RA Candidate Meets Endpoints in 3rd Phase III Study Zacks
Dec-20-17 11:25AM  Minerva Initiates Phase III Study on Schizophrenia Candidate Zacks
10:11AM  TherapeuticsMD Falls Despite Acceptance of NDA: Here's Why Zacks
Dec-19-17 12:31PM  ETFs with exposure to Celldex Therapeutics, Inc. : December 19, 2017 Capital Cube
Dec-14-17 10:09AM  Shire's New Formulation of Oncaspar Gets Approval in Europe Zacks
Dec-13-17 06:14PM  Celldex Therapeutics Inc (NASDAQ:CLDX)s Earnings Grew 23%, Is It Enough? Simply Wall St.
09:40AM  Glaxo's Nucala Label Expansion Application Gets FDA Approval Zacks
Dec-10-17 09:31AM  Why Celldex Therapeutics Stock Reversed Course in November Motley Fool
Dec-08-17 12:34PM  ETFs with exposure to Celldex Therapeutics, Inc. : December 8, 2017 Capital Cube
Dec-01-17 05:51PM  Celldex Begins Phase I Trial on Cancer Candidate CDX-1140 Zacks
09:33AM  Cancer Space Update: Pfizer's Bavencio Fails in Phase III Zacks
08:30AM  Report: Exploring Fundamental Drivers Behind Lannett, Oclaro, Antares Pharma, Workday, The Medicines, and Celldex Therapeutics New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Nov-30-17 09:19AM  Better Buy: Ziopharm Oncology Inc. vs. Celldex Therapeutics, Inc. Motley Fool
08:01AM  Celldex Therapeutics Initiates Phase 1 Study of New Product Candidate CDX-1140 in Solid Tumors GlobeNewswire
Nov-29-17 08:44AM  Here's Where Things Went Wrong for Celldex Therapeutics, Inc. in 2017 Motley Fool
Nov-22-17 07:20AM  Featured Company News - Celldex Starts Phase-2 Combination Study of CDX-3379 and Cetuximab in Head and Neck Squamous Cell Carcinoma ACCESSWIRE
Nov-20-17 12:01PM  ETFs with exposure to Celldex Therapeutics, Inc. : November 20, 2017 Capital Cube
09:33AM  Celldex (CLDX) Initiates Phase II Study on Cancer Candidate Zacks
Nov-17-17 08:01AM  Celldex Therapeutics Initiates Phase 2 Combination Study of CDX-3379 and Cetuximab in Head and Neck Squamous Cell Carcinoma GlobeNewswire
Nov-09-17 09:50AM  Celldex Therapeutics, Inc. :CLDX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017 Capital Cube
07:19AM  Celldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : November 9, 2017 Capital Cube
Nov-08-17 05:46PM  ETFs with exposure to Celldex Therapeutics, Inc. : November 8, 2017 Capital Cube
01:31PM  How to Invest in Biotech Stocks Motley Fool
10:11AM  Celldex (CLDX) Q3 Loss Narrows, Revenues Beat, Shares Up Zacks
08:00AM  Today's Research Reports on Trending Tickers: Celldex Therapeutics and Idera Pharmaceuticals ACCESSWIRE
Nov-07-17 07:08PM  How Much Did Celldex Therapeutics Incs (CLDX) CEO Pocket Last Year? Simply Wall St. +10.08%
01:02PM  Why Celldex Therapeutics Jumped Higher Today Motley Fool
12:36PM  Celldex Therapeutics, Inc.'s Most Important Takeaway From Q3 Isn't a Number Motley Fool
10:00AM  Why Celldex Therapeutics Stock Crumbled in October Motley Fool
08:11AM  Celldex reports 3Q loss Associated Press
08:01AM  Celldex Reports Third Quarter 2017 Results GlobeNewswire
Nov-06-17 09:52AM  Is Celldex Therapeutics Inc (CLDX) Undervalued? Simply Wall St.
Nov-01-17 11:56AM  Celldex (CLDX) to Report Q3 Earnings: What's in the Cards? Zacks
Oct-26-17 11:02AM  Celldex Therapeutics, Inc. Value Analysis (NASDAQ:CLDX) : October 26, 2017 Capital Cube -5.16%
Oct-25-17 08:14AM  Celldex Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CLDX-US : October 25, 2017 Capital Cube
Oct-17-17 06:17PM  Better Buy: Ziopharm Oncology, Inc. vs. Celldex Therapeutics Motley Fool
Oct-06-17 03:13PM  What's Behind Celldex Therapeutics, Inc.'s 16% Rally in September? Motley Fool
Oct-03-17 08:00AM  Celldex Therapeutics Appoints Margo Heath-Chiozzi, M.D., as Senior Vice President, Regulatory Affairs GlobeNewswire
Oct-02-17 03:27PM  How Does Investing In Celldex Therapeutics Inc (CLDX) Impact Your Portfolio? Simply Wall St.
Sep-26-17 10:46AM  ETFs with exposure to Celldex Therapeutics, Inc. : September 26, 2017 Capital Cube -9.33%
08:10AM  Today's Research Reports on Trending Tickers: Celldex Therapeutics and Genocea Biosciences ACCESSWIRE
Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of various immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer; and CDX-3379, a human monoclonal antibody that is in Phase II study in combination with cetuximab for the treatment of head and neck squamous cell carcinoma. The company also develops earlier stage drug candidates that are in clinical development, including CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers; CDX-1140, a human monoclonal antibody; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-1401, an immunotherapeutic aimed at antigen presenting cells for cancer indications. Celldex Therapeutics, Inc. has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; University of Southampton; Amgen Inc.; Amgen Fremont; Seattle Genetics, Inc.; Yale University; and MedImmune, LLC. The company is headquartered in Hampton, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KELER TIBORExecutive VP & CSOJun 15Buy0.5916,5009,78335,368Jun 18 08:15 AM